Conference Coverage

Endarterectomy and stenting have similar efficacy in carotid stenosis


 

REPORTING FROM ISC 2019

Carotid endarterectomy and carotid artery stenting with embolic protection have comparable efficacy and safety for asymptomatic patients with severe carotid artery stenosis, according to a pooled analysis presented at the International Stroke Conference sponsored by the American Heart Association. The treatments have similar rates of procedural complications and 4-year ipsilateral stroke, said Jon S. Matsumura, MD, chairman of the division of vascular surgery at the University of Wisconsin in Madison.

Asymptomatic severe carotid stenosis is the most common indication for carotid operations in the United States. Data support carotid endarterectomy in selected asymptomatic patients. Carotid artery stenting with embolic protection is a newer treatment option. Two of the five most recent large, randomized trials – CREST and ACT I – compared carotid stenting with endarterectomy in asymptomatic patients. Dr. Matsumura and his colleagues conducted a pooled analysis of these two trials to help inform the choice of treatment.

The investigators analyzed data from the CREST and ACT I studies, which had many similarities. The researchers in these trials carefully selected the surgeons and the interventionalists who participated in them. Each trial used single carotid stent systems, and both trials used routine, distally placed embolic protection. The trials had independent neurologic assessment, routine cardiac enzyme screening, and central clinical and adjudication committees.

Dr. Matsumura and his colleagues decided to conduct a patient-level pooled analysis and defined the primary endpoint as a composite of death, stroke, and myocardial infarction in the periprocedural period and any ipsilateral stroke within 4 years of randomization. They included in their analysis all randomized, asymptomatic patients who were younger than 80 years.

Pages

Recommended Reading

ICYMI: Andexanet alfa reduces anti–factor Xa activity from apixaban, rivaroxaban
MDedge Neurology
Hormone therapy in transgender individuals may up risk of CV events
MDedge Neurology
Noncardiac surgery has 7% covert stroke rate in elderly
MDedge Neurology
Stroke endovascular therapy: The more you do, the better you do
MDedge Neurology
Stroke thrombolysis looks safe 31+ days after prior stroke
MDedge Neurology
Glyceryl trinitrate does not improve outcomes of ischemic stroke
MDedge Neurology
Higher blood pressure after thrombectomy links with bad stroke outcomes
MDedge Neurology
MI, strokes spike during 30 days after cancer diagnosis
MDedge Neurology
Second-generation hydrogel surpasses platinum for brain aneurysm closure
MDedge Neurology
Injectable nimodipine does not improve outcomes of subarachnoid hemorrhage
MDedge Neurology